Lantheus Signs $8 Billion Merger with Curium to Build 70-Country Radiopharmaceutical Network

The pending Lantheus-Curium merger will consolidate radiopharmaceutical manufacturing and distribution across more than 70 countries, creating immediate compliance and supply-chain planning obligations for QA directors and plant heads operating in nuclear medicine today. Announced on August 3, 2026, the all-cash transaction values Lantheus at up to approximately $8.0 billion, with Curium US Holdings LLC acquiring all outstanding Lantheus shares at $102.50 per share at closing, plus non-transferable Contingent Value Rights of up to $12.00 per share tied to commercial milestones through 2030.

The combined entity will span diagnostics and therapeutics, integrating Lantheus's established radiopharmaceutical portfolio with Curium's existing international manufacturing infrastructure. For regulatory affairs leads, the multi-jurisdictional footprint raises immediate questions around GMP harmonisation across sites subject to differing national competent authority standards, ICH Q10 alignment, and the coordination of post-merger process validation programmes where manufacturing site changes may trigger supplemental filings under 21 CFR Part 211 and equivalent international frameworks.

Lantheus posted worldwide revenue of $388.2 million for Q2 2026, a 2.7% increase year-over-year, though adjusted net income declined 5.1% to $104.9 million. PYLARIFY sales of $240.4 million represented a 4.1% decrease, while DEFINITY grew 5.2% to $88.3 million. Operating income rose 13.9% to $100.2 million on a GAAP basis, with free cash flow of $89.9 million providing a measure of pre-merger financial stability relevant to integration planning timelines.

In connection with the pending transaction, Lantheus has suspended its full year 2026 financial guidance and will not host a Q2 earnings call, limiting near-term visibility for supply chain partners and contract manufacturers currently aligned to Lantheus production schedules. The Lantheus Board of Directors unanimously approved the transaction; regulatory and shareholder approvals remain outstanding.

The CVR structure, contingent on specified commercial milestones for Lantheus products through 2030, means sterility assurance levels and product lifecycle management across the combined portfolio will carry direct financial consequences well beyond the close date.

Source: Lantheus Holdings, Inc. via GlobeNewswire, August 6, 2026. No earnings call was held in connection with Q2 2026 results.